Neuentwicklungen in der Thrombozytenaggregationshemmung – sinnvolle Alternativen für ASS/Clopidogrel-Non-Responder?

Antiplatelet Trialists Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy- I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106 Belhassen L, Pelle G, Dubois-Rande JL et al (2003) Improved endothelial function by the thromboxane A2 receptor antagonist S188886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41:1198–1204 Bhatt DL, Kapadia SR, Bajzer CT et al (2001) Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 13:767–771 Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, DISPERSE-2 Investigators (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50:1844–1851 Eikelboom JW, Hirsh J, Weitz JI et al (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655 Emanuelsson H, Mahaffey K, Harrington R, Husted S, Storey RF, Sanders N, Peters G, Cannon CP (2006) Can greater inhibition of platelet aggregation be tolerated? Evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). J Am Coll Cardiol 47 (Suppl A):212A Frossard M, Fuchs I, Leitner JM et al (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110:1392–1397 Fuchs I, Frossard M, Spiel A et al (2006) Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 4:2547–2552 Geisler T, Grass D, Bigalke B et al (2008) The PREDICT (residual platelet aggregation after deployment of intracoronary stent)-score. J Thromb Haemost 6:54–61 Geisler T, Gawaz M (2008) Resistenz gegenüber Plättchenfunktionshemmern: ein reales Problem. Herz 33:260–268 Görlinger K, Jambor C, Dirkmann D, Dusse F, Hanke A, Adamzik M, Hartmann M, Philipp S, Weber AA, Rahe-Meyer N (2008) Messung der Thrombozytenfunktion mit Point-of-Care-Methoden. Herz 33: 297–305 Greenbaum A, Grines C, Bittl J, Becker R, Kereiakes D (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary interventions: Results from a 2-part, Phase II, multicenter, randomized, placeboand acitive-controlled trial. Am Heart J 151:689.e681–689.e610 Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistence among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965 Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006) Pharmacodynamics, pharmacinetics, and safety of oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidrogrel with aspirin. Eur Heart J 27:1038–1047 ISIS-2 (Second international study of infarct survival) collaborative group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360 Kleinschnitz C, Pozgajova M, Pham M et al (2007) Targeting platelets in acute experimental stroke: impact of glycoprotein I b, VI, and II b/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 115:2323–2330 Krötz F, Sohn HY, Klauss V (2008) Antiplatelet drugs in cardiological practice: Established strategies and new developments. Vasc Health Risk Manag 4:637–645 Leger AJ, Covic L, Kuliopulos A (2006) Protease-activated receptors in cardiovascular diseases. Circulation 114:1070–1077 Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing precutaneous coronary interventions: the PCI-CURE study. Lancet 358:527–533 Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E, for the TRITON-TIMI 38 Investigators (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29:2473–2479 Neri Serneri GG, Coccheri S, Marubini E et al (2004) Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 25:1845–1852 Steinhubl SR, Berger PB, Mann JT et al (2002) CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary interventions: a randomized controlled trial. JAMA 288:2411–2420 Steinhubl S, Roe MT (2007) Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovasc Drugs Rev 25:188–203 Storey RF (2006) Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 12:1255–1259 Vilahur G, Casani L, Badimon L (2007) A thromboxane A2/prostaglandin H2 receptor antagoonist (S188886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 98:662–669 Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FWA, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, for the TRITON-TIMI 38 Investigators (2008) Greater clinical benefit of more intensive oral platelet therapy with prasugrel in patients with diabetes mellitus in the Trial to assess Improvment in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis In Myocardial Infarction 38. Circulation 118:1626–1636 Worth NF, Berry CL, Thomas AC et al (2005) S18885, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183:65–73 Zimmermann N, Weber AA, Hohlfeld T (2008) Aspirin „Resistance“. Herz 33:270–278